Supplementary Figure 1. Study design



ICF, informed consent form; MRI, magnetic resonance imaging; W, week.

Primary endpoint: the proportion of patients with combined remission at Week 24

Secondary endpoints: clinical remission, response, time to combined remission, time to clinical remission, time to response at Week 24 and Week 52, and proportion of patients who relapsed among those who had combined remission at Week 24.

The ADMIRE-CD study visits: Week 6, 12, 18, 24, 36, 52, 78 and 104.